title: Predictors of the rate of BMD loss in older men: findings from the CHAMP study.
abstract: Though bone loss tends to accelerate with age there are modifiable factors that may influence the rate of bone loss even in very old men.
  
  
  BACKGROUND
  The aim of this 2-year longitudinal study was to examine potential predictors of change in total hip bone mineral density (BMD) in older men.
  
  
  METHODS
  The Concord Health and Ageing in Men Project is a population-based study in Sydney, Australia. For this study, 1,122 men aged 70-97 years had baseline and follow-up measures of total hip BMD measured with dual X-ray absorptiometry. Data about mobility, muscle strength, balance, medication use, cognition, medical history and lifestyle factors were collected using questionnaires and clinical assessments. Serum 25-hydroxyvitamin D [25(OH)D] was also measured. Multivariate linear regression models were used to assess relationships between baseline predictors and change in BMD.
  
  
  RESULTS
  Over a mean of 2.2 years, there was a mean annualised loss of total hip BMD of 0.006 g/cm(2)/year (0.6 %) and hip BMC of 0.14 g/year (0.3 %). Annual BMD loss accelerated with increasing age, from 0.4 % in men aged between 70 and 75 years, to 1.2 % in men aged 85+ years. In multivariate regression models, predictors of faster BMD loss were anti-androgen, thiazolidinedione and loop-diuretic medications, kidney disease, poor dynamic balance, larger hip bone area, older age and lower serum 25(OH)D. Factors associated with attenuated bone loss were walking for exercise and use of beta-blocker medications. Change in BMD was not associated with baseline BMD, smoking, alcohol consumption, BMI, frailty, or osteoarthritis.
  
  
  CONCLUSIONS
  There was considerable variation in the rate of hip bone loss in older men. Walking, better balance and beta blockers may attenuate the acceleration of BMD loss that occurs with age.
authors.affiliation: School of Public Health, University of Sydney, PO Box 1770 Chatswood, Concord, NSW 2057-2139, Australia. kerrinb542@gmail.com
authors.forename: K
authors.initials: K
authors.lastname: Bleicher
authors.forename: R G
authors.initials: RG
authors.lastname: Cumming
authors.forename: V
authors.initials: V
authors.lastname: Naganathan
authors.forename: M J
authors.initials: MJ
authors.lastname: Seibel
authors.forename: F M
authors.initials: FM
authors.lastname: Blyth
authors.forename: D G
authors.initials: DG
authors.lastname: Le Couteur
authors.forename: D J
authors.initials: DJ
authors.lastname: Handelsman
authors.forename: H M
authors.initials: HM
authors.lastname: Creasey
authors.forename: L M
authors.initials: LM
authors.lastname: Waite
mesh_terms: D015502:Absorptiometry, Photon / Q000379:methods; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D015519:Bone Density / Q000502:physiology*; D018450:Disease Progression; D006621:Hip Joint / Q000503:physiopathology; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D053580:Muscle Strength / Q000502:physiology; D009517:New South Wales / Q000453:epidemiology; D010024:Osteoporosis / Q000453:epidemiology / Q000503:physiopathology*; D012307:Risk Factors; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D016138:Walking / Q000502:physiology
chemical_list: D014807:Vitamin D; C104450:25-hydroxyvitamin D